Detalles de la búsqueda
1.
Risk factors for cardiovascular events and mortality in patients diagnosed with diffuse large B-cell lymphoma and treated with anthracyclines.
Hematol Oncol
; 40(4): 626-636, 2022 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-35644011
2.
Aggressive lymphoma subtype is a risk factor for venous thrombosis. Development of lymphoma - specific venous thrombosis prediction models.
Am J Hematol
; 95(8): 918-926, 2020 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-32311162
3.
Gastrointestinal Microbiome and Mycobiome Changes during Autologous Transplantation for Multiple Myeloma: Results of a Prospective Pilot Study.
Biol Blood Marrow Transplant
; 25(8): 1511-1519, 2019 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-30959164
4.
Low-Dose Azacitidine with DNMT1 Level Monitoring to Treat Post-Transplantation Acute Myelogenous Leukemia or Myelodysplastic Syndrome Relapse.
Biol Blood Marrow Transplant
; 25(6): 1122-1127, 2019 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-30599207
5.
Comparative Analysis of Calcineurin Inhibitor-Based Methotrexate and Mycophenolate Mofetil-Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation.
Biol Blood Marrow Transplant
; 25(1): 73-85, 2019 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30153491
6.
Dual institution experience of nodal marginal zone lymphoma reveals excellent long-term outcomes in the rituximab era.
Br J Haematol
; 175(2): 275-280, 2016 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-27443247
7.
Dual institution experience of extranodal marginal zone lymphoma reveals excellent long-term outcomes.
Br J Haematol
; 173(3): 404-12, 2016 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-26953041
8.
Prevention and Treatment of Cancer-Related Infections, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 14(7): 882-913, 2016 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-27407129
9.
Comparison of 2 Carmustine-Containing Regimens in the Rituximab Era: Excellent Outcomes Even in Poor-Risk Patients.
Biol Blood Marrow Transplant
; 21(11): 1926-31, 2015 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-26087475
10.
Hematopoietic Progenitor Cell Harvesting Is Feasible after Treatment with Brentuximab Vedotin in CD30(+) Lymphoma Patients Who Received Multiple Prior Lines of Treatment.
Biol Blood Marrow Transplant
; 21(8): 1529-1531, 2015 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-25937397
11.
Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research.
Biol Blood Marrow Transplant
; 21(2): 266-74, 2015 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-25445023
12.
Allotransplantation for patients age ≥40 years with non-Hodgkin lymphoma: encouraging progression-free survival.
Biol Blood Marrow Transplant
; 20(7): 960-8, 2014 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-24641829
13.
Reduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukemia patients undergoing hematopoietic cell transplant during the tyrosine kinase inhibitor era.
Blood
; 119(17): 4083-90, 2012 Apr 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-22408257
14.
Lenalidomide, rituximab (R2), and ixazomib for frontline treatment of high risk follicular and indolent non-Hodgkin lymphoma.
Leuk Lymphoma
; 65(6): 768-773, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38456694
15.
Flow cytometry of DNMT1 as a biomarker of hypomethylating therapies.
Cytometry B Clin Cytom
; 106(1): 11-24, 2024 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38345160
16.
A multicenter study of posttransplantation low-dose inotuzumab ozogamicin to prevent relapse of acute lymphoblastic leukemia.
Blood Adv
; 8(6): 1384-1391, 2024 Mar 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-38170741
17.
Phase I study of intra-osseous co-transplantation of a single-unit cord blood and mesenchymal stromal cells with reduced intensity conditioning regimens.
Front Oncol
; 13: 1186532, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37207167
18.
Gilteritinib in Combination With Induction and Consolidation Chemotherapy and as Maintenance Therapy: A Phase IB Study in Patients With Newly Diagnosed AML.
J Clin Oncol
; 41(26): 4236-4246, 2023 09 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37379495
19.
A Phase I Study to Determine the Maximum Tolerated Dose of ex Vivo Expanded Natural Killer Cells Derived from Unrelated, HLA-Disparate Adult Donors.
Transplant Cell Ther
; 28(5): 250.e1-250.e8, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35172204
20.
Targeted Marrow Irradiation Intensification of Reduced-Intensity Fludarabine/Busulfan Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation.
Transplant Cell Ther
; 28(7): 370.e1-370.e10, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35421620